Pfizer breast cancer drug fails late-stage test
Pfizer breast cancer drug fails late-stage test
October 09, 2020
Pfizer says its cancer drug Ibrance did not meet the main goal in a late-stage trial in patients with a type of breast cancer.
Post A Comment:
0 comments:
Leave a comment. Thanks!